PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsParathyroid hormone
Natpara, Natpar(parathyroid hormone)
Natpar, Natpara (parathyroid hormone) is a protein pharmaceutical. Parathyroid hormone was first approved as Natpara on 2015-01-23. It is used to treat hypocalcemia and hypoparathyroidism in the USA. It has been approved in Europe to treat hypoparathyroidism. It is known to target prolactin-releasing peptide receptor, parathyroid hormone 2 receptor, and parathyroid hormone/parathyroid hormone-related peptide receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Natpara
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Parathyroid hormone
Tradename
Proper name
Company
Number
Date
Products
Natparaparathyroid hormoneTakedaN-125511 RX2015-01-23
4 products
Labels
FDA
EMA
Brand Name
Status
Last Update
natpara (parathyroid hormone)Biologic Licensing Application2023-05-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypocalcemiaHP_0002901D006996E83.51
hypoparathyroidism—D007011E20
Agency Specific
FDA
EMA
Expiration
Code
parathyroid hormone, Natpara, Takeda Pharmaceuticals U.S.A., Inc.
2122-01-23Orphan excl.
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H05: Calcium homeostasis
— H05A: Parathyroid hormones and analogues
— H05AA: Parathyroid hormones and analogues
— H05AA03: Parathyroid hormone
HCPCS
No data
Clinical
Clinical Trials
482 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Shoulder fracturesD012784—S42.9———1—1
Bone fracturesD050723EFO_0003931T14.8———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteoporosisD010024EFO_0003882M81.0——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vitamin d deficiencyD014808EFO_0003762E551————1
Healthy volunteers/patients———1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoparathyroidismD007011—E20————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameParathyroid hormone
INNparathyroid hormone
Description
Parathyroid hormone (PTH), also called parathormone or parathyrin, is a peptide hormone secreted by the parathyroid glands that regulates the serum calcium concentration through its effects on bone, kidney, and intestine.
Classification
Protein
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
>3FFD:A|Monoclonal antibody, heavy chain, Fab fragment EVQLVESGGDLVKPGGSLKLSCAASGFTFSSYGMSWIRQTPDKRLEWVATISSGGSYTYYPDSVKGRFTISRDNAKNTLY LQMSSLKSEDTAMFYCARQTTMTYFAYWGQGTLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWN SGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSPRPSETVTCNVAHPASSTKVDKKIEPA >3FFD:B|Monoclonal antibody, light chain, Fab fragment QLVLTQSSSASFSLGASAKLTCTLSSQHSTYTIEWYQQQPLKPPKYVMDLKQDGSHSTGDGIPDRFSGSSSGADRYLSIS NIQPEDEAMYICGVGDTIKEQFVYVFGGGTKVTVLGEPKSTPTLTVFPPSSEELKENKATLVCLISNFSPSGVTVAWKAN GTPITQGVDTSNPTKEGNKFMASSFLHLTSDQWRSHNSFTCQVTHEGDTVEKSLSPAECL
Identifiers
PDB1BL1, 1BWX, 1BZG, 1ET1, 1FVY, 1HPH, 1HPY, 1HTH, 1M5N, 1ZWA, 1ZWB, 1ZWC, 1ZWD, 1ZWE, 1ZWF, 1ZWG, 2L1X, 3C4M, 3FFD, 3H3G, 3L2J, 4YD8, 4Z8J, 5EMB, 6FJ3, 6NBF, 6NBH, 6NBI, 6XT9, 7F16, 7UZO, 7UZP, 7VVJ, 7VVK, 7VVL, 7VVM, 7VVN, 7VVO, 7Y35, 7Y36, 8BIA, 8BJ0, 8D51, 8D52, 8FLQ, 8FLR, 8FLS, 8FLT, 8FLU, 8GW8, 8HA0, 8HAF, 8HAO, 8JR9, 8T5F
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL2108078
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDN19A0T0E5J (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
PRLHR
PRLHR
PTH2R
PTH2R
PTH1R
PTH1R
Organism
Homo sapiens
Gene name
PRLHR
Gene synonyms
GPR10, GR3
NCBI Gene ID
2834
Protein name
prolactin-releasing peptide receptor
Protein synonyms
G-protein coupled receptor 10, hGR3, prRP receptor
Uniprot ID
Q5VXR9
Mouse ortholog
Prlhr (226278)
prolactin-releasing peptide receptor (Q6VMN6)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Natpara – Takeda
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Natpara – Shire
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 85,661 documents
View more details
Safety
Black-box Warning
Black-box warning for: Natpara (parathyroid hormone)
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
4,453 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use